Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”
- 11 December 2012
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 5 (254) , lc5
Abstract
Targeted inhibitors used in cancer treatments may have adverse effects on immune responses.Keywords
This publication has 4 references indexed in Scilit:
- Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 SignalingScience Signaling, 2012
- Antiviral applications of Toll-like receptor agonistsJournal of Antimicrobial Chemotherapy, 2012
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialThe Lancet Oncology, 2011
- The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory ResponseImmunity, 2008